Expert Perspectives in HF Lesson 4: Integrating Sacubitril/Valsartan

PROGRAM DESCRIPTION In 2015, the US Food and Drug Administration (FDA) approved sacubitril/valsartan, making it one of the first pharmacologic therapies to emerge for chronic heart failure (HF) management in ...

PROGRAM DESCRIPTION
In 2015, the US Food and Drug Administration (FDA) approved sacubitril/valsartan, making it one of the first pharmacologic therapies to emerge for chronic heart failure (HF) management in more than a decade. Sacubitril/valsartan approval was based primarily on the results of the PARADIGM-HF study, which randomized 8442 patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) to either sacubitril/valsartan or enalapril. After a median follow-up of 27 months, sacubitril/valsartan treatment was associated with a 20% reduction in the combined primary end point of death or HF hospitalization and a 16% reduction in all-cause death compared with enalapril. Education is needed on how sacubitril/valsartan can be incorporated into treatment planning for chronic HF.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be better able to:Evaluate the safety, efficacy, and mechanism of action (MOA) of sacubitril/valsartanUtilize sacubitril/valsartan in patients as appropriate

---

Write the first review

Resource tags